James E. Butrynski

Sarah Cannon — United States

Medicine · Health Sciences

29h-index4.8kcitations75works8.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(33), Lung Cancer Treatments and Mutations(17), Gastrointestinal Tumor Research and Treatment(14), Neuroblastoma Research and Treatments(13), Neuroendocrine Tumor Research Advances(10)

Publications75 total

Testing and treatment patterns in <i>KRAS</i> mutant mNSCLC: Results from the MYLUNG Consortium.
Journal of Clinical Oncology·2025
733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03
Annals of Oncology·2024· 2 citedOpen Access
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Journal of Clinical Oncology·2024· 39 citedOpen Access
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium
Journal of the Advanced Practitioner in Oncology·2024Open Access
Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.
Journal of Clinical Oncology·2024· 1 cited
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
Journal of Clinical Oncology·2023· 6 cited
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
Journal of Clinical Oncology·2023· 7 cited
Supplementary Figure Legend from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Supplementary Table 1 from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Data from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Data from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Supplementary Figure Legend from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Supplementary Figure 1 from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Supplementary Figure 1 from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Supplementary Table 1 from The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
2023Open Access
Impact of oncology clinical pharmacist intervention on clinical trial enrollment in The U.S. Oncology Network’s MYLUNG Consortium.
Journal of Clinical Oncology·2022
P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study
Journal of Thoracic Oncology·2021· 1 cited
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Sarcoma·2020· 26 citedOpen Access
Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Clinical Trials·2019· 1 cited
Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research·2019· 15 cited
page 1 of 4Next →

Frequent Co-authors

Suzanne George(15), George D. Demetri(14), Jeffrey A. Morgan(13), Andrew J. Wagner(12), Edwin Choy(8), Jason L. Hornick(7), Nikhil H. Ramaiya(7), David C. Harmon(7), David R. D’Adamo(6), Michael C. Heinrich(6), Margaret von Mehren(6), Annick D. Van den Abbeele(5), Chandrajit P. Raut(5), Sant P. Chawla(5), Scott H. Okuno(5), Kristen N. Ganjoo(5), Geoffrey I. Shapiro(4), Jeffrey T. Yap(4), Scott M. Schuetze(4), Christopher L. Corless(4)